Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Odyssey Therapeutics Withdraws IPO Application Amid Challenging Biotech Market

Odyssey Therapeutics, a Massachusetts-based immune-focused biotech company, has withdrawn its application for an initial public offering (IPO) on the Nasdaq, citing that going public "is not in the best interests of the company." The decision comes nearly five months after the company initially filed for an IPO in January, reflecting the current challenges facing the biotech IPO market.

NoahAI News6/10/2025

Merck's Enflonsia Approval Sets Stage for RSV Market Battle

The U.S. Food and Drug Administration (FDA) has approved Merck's monoclonal antibody clesrovimab, to be marketed as Enflonsia, for the prevention of respiratory syncytial virus (RSV)-related lower respiratory tract disease in newborns and infants. This approval marks a significant development in the pharmaceutical industry's efforts to combat RSV, a leading cause of hospitalizations among infants in the United States.

NoahAI News6/10/2025

FDA Halts Multiple Gilead HIV Combination Therapy Trials Amid Safety Concerns

Gilead Sciences, a leading pharmaceutical company, has encountered a significant setback in its HIV treatment development program. The U.S. Food and Drug Administration (FDA) has imposed a clinical hold on five trials involving Gilead's experimental HIV combination therapy, citing safety issues. This development has sent ripples through the pharmaceutical industry and impacted Gilead's stock performance.

NoahAI News6/10/2025

Medtronic Appoints Kate Benedict as President of Acute Care and Monitoring Business

Medtronic, a global leader in medical technology, has announced the appointment of Kate Benedict as the new president of its Acute Care and Monitoring business. This strategic move comes as part of the company's ongoing efforts to strengthen its leadership team and consolidate its operations in the medical surgical portfolio.

NoahAI News6/10/2025

Pfizer's $6B Bet on PD-1xVEGF Bispecific: A Strategic Move in Oncology

Pfizer CEO Albert Bourla has shed light on the company's recent $1.25 billion upfront investment in 3SBio's PD-1xVEGF bispecific antibody, SSGJ-707. The deal, which could potentially reach $6 billion, marks Pfizer's entry into the increasingly competitive field of bispecific antibodies targeting PD-1 and VEGF pathways in oncology.

NoahAI News6/10/2025

National Resilience Announces Major Consolidation, Closing 6 of 10 Plants

National Resilience, a contract development and manufacturing organization (CDMO) established in 2020, has announced a significant restructuring of its operations. The company will close six of its ten manufacturing plants and continue as a streamlined CDMO, focusing on high-growth segments in cell-based medicines, biologics, and aseptic drug product operations.

NoahAI News6/10/2025

Recursion Pharmaceuticals Announces Layoffs Amid Pipeline Restructuring

Recursion Pharmaceuticals, a leading AI-driven biotech company, has announced a significant workforce reduction as part of its ongoing efforts to streamline operations and focus on key therapeutic areas. The move comes in the wake of recent pipeline cutbacks and follows the company's high-profile acquisition of Exscientia in 2024.

NoahAI News6/10/2025

National Resilience Scales Back Operations Amid Industry Slowdown

National Resilience, a well-funded startup launched in 2020 to support drug production for young biotechnology companies, announced plans to significantly scale back its operations. The move comes as the company's rapid expansion has outpaced industry demand, particularly in the gene and cell therapy sectors.

NoahAI News6/10/2025

Odyssey Therapeutics Abandons IPO Plans Amid Challenging Biotech Market

Odyssey Therapeutics, a biotech company focused on autoimmune and inflammatory diseases, has withdrawn its plans for an initial public offering (IPO), citing unfavorable market conditions. This decision underscores the ongoing challenges faced by biotech firms seeking to go public in the current economic climate.

NoahAI News6/10/2025

Activist Investor Pushes for Further Cost Cuts at Keros Therapeutics Amid Ongoing Restructuring

Keros Therapeutics, a Massachusetts-based biotech company, faces increasing pressure from activist investor ADAR1 Capital Management to implement more aggressive cost-cutting measures, just weeks after announcing significant layoffs and a shift in strategic focus.

NoahAI News6/10/2025

CDC's Vaccine Committee Overhaul: Kennedy's Bold Move Reshapes Public Health Landscape

In a sweeping and controversial decision, Health and Human Services Secretary Robert F. Kennedy Jr. has "retired" all 17 members of the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP). This unprecedented move, announced on Monday, marks a significant shift in the oversight of vaccine recommendations in the United States and has sent shockwaves through the pharmaceutical industry and public health community.

NoahAI News6/10/2025

Merck's Enflonsia Enters RSV Prevention Market, Challenging Sanofi and AstraZeneca's Beyfortus

The Food and Drug Administration (FDA) has approved Merck's new antibody drug, Enflonsia (clesrovimab), for the prevention of respiratory syncytial virus (RSV) in newborns and infants. This approval marks a significant development in the RSV treatment landscape, setting the stage for increased competition in a market currently dominated by Sanofi and AstraZeneca's Beyfortus.

NoahAI News6/10/2025

«1...50 51 52...67 »